SEARCH

SEARCH BY CITATION

References

  • 1
    Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 2004; 4: 43747.
  • 2
    Wang GL, Jiang BH, Rue EA, et al . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995; 92: 551014.
  • 3
    Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2003; 2: 80311.
  • 4
    Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods Enzymol. 2007; 435: 385402.
  • 5
    Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today. 2007; 12: 8539.
  • 6
    Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 2007; 26: 34152.
  • 7
    Young RM, Wang SJ, Gordan JD, et al . Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem. 2008; 283: 1630919.
  • 8
    Chang H, Shyu KG, Lee CC, et al . GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem Biophys Res Commun. 2003; 302: 95100.
  • 9
    Greenberger LM, Horak ID, Filpula D, et al . A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008; 7: 3598608.
  • 10
    Rapisarda A, Uranchimeg B, Sordet O, et al . Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64: 147582.
  • 11
    Creighton-Gutteridge M, Cardellina JH, Stephen AG, et al . Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res. 2007; 13: 10108.
  • 12
    Sapra P, Zhao H, Mehlig M, et al . Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008; 14: 188896.
  • 13
    Laughner E, Taghavi P, Chiles K, et al . HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001; 21: 39954004.
  • 14
    Koukourakis MI, Simopoulos C, Polychronidis A, et al . The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status Anticancer Res. 2003; 23: 167380.
  • 15
    Luwor RB, Lu Y, Li X, et al . The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene. 2005; 24: 443341.
  • 16
    Newcomb EW, Ali MA, Schnee T, et al . Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy. Neuro Oncol. 2005; 7: 22535.
  • 17
    Mayerhofer M, Valent P, Sperr WR, et al . BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002; 100: 376775.
  • 18
    Majumder PK, Febbo PG, Bikoff R, et al . mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10: 594601.
  • 19
    Thomas GV, Tran C, Mellinghoff IK, et al . Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006; 12: 1227.
  • 20
    Han JY, Oh SH, Morgillo F, et al . Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst. 2005; 97: 127286.
  • 21
    Wang GL, Jiang BH, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun. 1995; 216: 66975.
  • 22
    Welsh SJ, Williams RR, Birmingham A, et al . The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003; 2: 23543.
  • 23
    Yang J, Ahmed A, Poon E, et al . Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol. 2009; 29: 224353.
  • 24
    Mabjeesh NJ, Escuin D, LaVallee TM, et al . 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003; 3: 36375.
  • 25
    Rapisarda A, Uranchimeg B, Scudiero DA, et al . Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002; 62: 431624.
  • 26
    Rapisarda A, Uranchimeg B, Sordet O, et al . Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64: 147582.
  • 27
    Rapisarda A, Zalek J, Hollingshead M, et al . Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004; 64: 68458.
  • 28
    Rapisarda A, Hollingshead M, Uranchimeg B, et al . Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009; 8: 186777.
  • 29
    Sapra P, Zhao H, Mehlig M, et al . Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008; 14: 188896.
  • 30
    Sapra P, Zhao H, Mehlig M, et al . Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008; 14: 188896.
  • 31
    Zhang H, Qian DZ, Tan YS, et al . Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008; 105: 1957986.
  • 32
    Klausmeyer P, Zhou Q, Scudiero DA, et al . Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii. J Nat Prod. 2009; 72: 80512.
  • 33
    Welsh S, Williams R, Kirkpatrick L, et al . Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther. 2004; 3: 23344.
  • 34
    Koh MY, Spivak-Kroizman T, Venturini S, et al . Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther. 2008; 7: 90100.
  • 35
    Zundel W, Schindler C, Haas-Kogan D, et al . Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; 14: 3916.
  • 36
    Majumder PK, Febbo PG, Bikoff R, et al . mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10: 594601.
  • 37
    Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008; 8: 85164.
  • 38
    Del BD, Ciuffreda L, Trisciuoglio D, et al . Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006; 66: 554954.
  • 39
    Wan X, Shen N, Mendoza A, et al . CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006; 8: 394401.
  • 40
    Majumder PK, Febbo PG, Bikoff R, et al . mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10: 594601.
  • 41
    Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009; 115: 361830.
  • 42
    Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007; 13: 680s4s.
  • 43
    Thomas GV, Tran C, Mellinghoff IK, et al . Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006; 12: 1227.
  • 44
    Motzer RJ, Bacik J, Murphy BA, et al . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 28996.
  • 45
    Motzer RJ, Escudier B, Oudard S, et al . Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 44956.
  • 46
    Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007; 32: 51730.
  • 47
    Isaacs JS, Jung YJ, Mimnaugh EG, et al . Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002; 277: 2993644.
  • 48
    Hur E, Kim HH, Choi SM, et al . Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol. 2002; 62: 97582.
  • 49
    Isaacs JS, Jung YJ, Mimnaugh EG, et al . Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem. 2002; 277: 2993644.
  • 50
    Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem. 2006; 6: 116371.
  • 51
    Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2008; 280: 14553.
  • 52
    Dioum EM, Chen R, Alexander MS, et al . Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009; 324: 128993.
  • 53
    Kong D, Park EJ, Stephen AG, et al . Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005; 65: 904755.
  • 54
    Lee K, Qian DZ, Rey S, et al . Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA. 2009; 106: 23538.
  • 55
    Olenyuk BZ, Zhang GJ, Klco JM, et al . Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA. 2004; 101: 1676873.
  • 56
    Kong D, Park EJ, Stephen AG, et al . Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005; 65: 904755.
  • 57
    Lee K, Qian DZ, Rey S, et al . Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA. 2009; 106: 23538.
  • 58
    Kung AL, Zabludoff SD, France DS, et al . Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004; 6: 3343.
  • 59
    Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997; 272: 226427.
  • 60
    Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 2006; 26: 5895907.
  • 61
    Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003; 10: 3619.
  • 62
    Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004; 22: 30411.
  • 63
    Mackay H, Hedley D, Major P, et al . A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005; 11: 552633.
  • 64
    Shin DH, Chun YS, Lee DS, et al . Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008; 111: 31316.
  • 65
    Shin DH, Chun YS, Lee DS, et al . Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood. 2008; 111: 31316.